Athira Pharma, Inc.

Clinical stage development of regenerative therapeutics for neurodegenerative disease

Athira has developed a proprietary small molecule platform which repairs neuronal function centrally and in the peripheral nervous system, using a novel regenerative method of action that targets the hepatocyte growth factor (HGF) pathway. Athria's lead compound, NDX-1017, is entering Phase 2 clinical trials and will be rapidly advanced utilizing a capital efficient strategy targeting cognitive enhancement followed by the ultimate goal of disease modification.